Agenus expands deal with GlaxoSmithKline; Nuron in-licenses vaccines
US biotech firm Agenus (Nasdaq: AGEN) says it has amended the QS-21 license and manufacturing agreement with UK pharma giant GlaxoSmithKline (LSE: GSK) to include additional rights for the use of Agenus' proprietary QS-21 Stimulon adjuvant in GSK Biologicals' adjuvant systems.
In addition, Agenus has agreed to grant the vaccines company the first right to negotiate for the purchase of Agenus or certain of its assets. The first right to negotiate will expire after five years.
Under the terms of the accord, GSK will pay Agenus a non-refundable $9 million, of which $2.5 million is creditable against future manufacturing technology transfer royalty payments. The deal also includes royalty payments for an undisclosed indication on commercialization of a vaccine product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze